XORTX Therapeutics Inc. (XRTX)
About XORTX Therapeutics Inc.
XORTX Therapeutics Inc is a clinical-stage pharmaceutical company focused on developing therapies to treat gout and progressive kidney disease modulated by aberrant purine and uric acid metabolism in orphan disease indications such as allopurinol-intolerant gout and autosomal dominant polycystic kidney disease, as well as more prevalent type 2 diabetic nephropathy and fatty liver disease. Its focus is on developing products to slow and/or reverse the progression of these diseases. The Company operates in one reportable operating segment: the development and commercialization of therapies to treat hyperuricemia-related diseases.
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
Financial summary
- Market cap
- $3.8M
15-minute delayed · data by Polygon.io
Past year · hover for prices
52-week range
- Market cap
- $3.8M
- Shares outstanding
- 1.9M
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- May 4, 2018
XORTX Therapeutics Inc. (XRTX) Stock Price
- Trading 63% below its 52-week high.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
No reviews yet. Be the first to review XORTX Therapeutics Inc..
Write a review
News about XORTX Therapeutics Inc.
News & sentiment via Polygon.io
XORTX Therapeutics Inc.: frequently asked questions
Is XORTX Therapeutics Inc. an American company?
XORTX Therapeutics Inc. is a US-based company, listed in the americancompanies.com directory of American companies. Its American-origin credentials have not yet been independently verified.
Is XORTX Therapeutics Inc. publicly traded?
Yes — XORTX Therapeutics Inc. is a publicly traded company. Its stock trades under the ticker symbol XRTX on the NASDAQ.
What does XORTX Therapeutics Inc. do?
XORTX Therapeutics Inc. is an American Pharmaceuticals company in the Health & Beauty sector.
